An immunomodulator with diverse biological activities
Roquinimex is an immunomodulator with diverse biological activities.1,2,3,4 In vivo, roquinimex (80 mg/kg) increases the number of myocardial MHC class II-expressing cells, the ratio of cytotoxic to helper T cells, and survival and decreases necrotic lesion area in a mouse model of murine coxsackievirus B3-induced myocarditis.1 It induces IFN-γ production, reduces TNF-α and IL-1β production, prevents the development of proteinuria, and ameliorates nephritis in a mouse model of chronic graft versus host disease (GVHD).2 Roquinimex (300 mg/kg) decreases colonic myeloperoxidase (MPO) activity and mucosal damage in a mouse model of colitis induced by dextran sulfate .3 It also decreases tumor weight and tumor blood flow in a von Hippel-Lindau (VHL) type 2a paraganglioma mouse xenograft model.4
1.Ilb?ck, N.G., Fohlman, J., Slorach, S., et al.Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine coxsackievirus B3 myocarditisJ. Immunol.142(9)3225-3228(1989) 2.Xiao, Z.-Y., Zhou, W.-X., Zhang, Y.-X., et al.Roquinimex-mediated protection effect on the development of chronic graft-versus-host disease in mice is associated with induction of Th1 cytokine production and inhibition of proinflammatory cytokine productionLife Sci.81(19-20)1403-1410(2007) 3.Liu, Q., Wang, Y., Wan, M.X., et al.Roquinimex inhibits dextran sodium sulfate-induced murine colitisInflamm. Res.52(2)64-68(2003) 4.Gross, D.J., Reibstein, I., Weiss, L., et al.The antiangiogenic agent linomide inhibits the growth rate of Von Hippel-Lindau paraganglioma xenografts to miceClin. Cancer Res.5(11)3669-3675(1999)
动态评分
0.0